MMLV, with higher processivity
- Discontinued Patent
In the Public Domain since
13 Nov 2018
Description
Methods for expressing recombinant Moloney Murine Leukemia Virus (MMLV) reverse transcriptase
Abstract
This invention provides recombinant murine leukemia virus reverse transcriptases, genes encoding these proteins and expression methods. The said murine leukemia virus reverse transcriptases are a series of MLV-RT proteins wherein the 84th amino acid residue (Q84) from the N-terminus is replaced with amino acid X, which is an amino acid with a side chain shorter than glutamine. The said murine leukemia virus reverse transcriptases have higher enzyme activity and processivity than the wild type enzyme, and are expected to be widely used in the field of biotechnology for cDNA synthesis.
Category
Others > COVID-19, Enzymes > Reverse Transcriptases
Related Inventors
unknown
Source
US Patent No 7,794,996
Patent Title: Recombinant murine leukemia virus reverse transcriptases, the genes encoding and the method for expressing it